Garlick: Development of ctDNA; $340M invested; advice on taking new technology into your labs and to patients? #PMWC17
5:10pm January 24th 2017 via Twitter Web Client
Tsongalis: The complexity of the question (regarding panels, tests) not answerable by a repository #PMWC17
5:09pm January 24th 2017 via Twitter Web Client
Tsongalis: Feels inspection needs to be tightened, can be improved. Need to publish validation as often as they can #PMWC17
5:07pm January 24th 2017 via Twitter Web Client
Garlick: Outgoing FDA commissioner and transparency? Aisner: You get samples via CAP, or other sources. Then PT to show it. #PMWC17
5:06pm January 24th 2017 via Twitter Web Client
Tsongalis: Very difficult to find people with NGS experience - 'the biggest challenge of my career'. Some techs - can't get trained. #PMWC17
5:03pm January 24th 2017 via Twitter Web Client
Tsongalis: Need LOD for various types of mutations; different opinions, can't skimp on. Impacts life-extending Rx #PMWC17
5:02pm January 24th 2017 via Twitter Web Client
Tsongalis: How about validating a whole exome? How many samples would you need for every mutation? #PMWC17
5:01pm January 24th 2017 via Twitter Web Client
Tsongalis: A lucky catch, by sharing samples. Specimens for eval, validation, proficiency needed but hard to get. #PMWC17
Tsongalis: Weekly basis 'we look at metrics that we never thought we'd have to look at before' #PMWC17
5:00pm January 24th 2017 via Twitter Web Client
Tsongalis: Went back, looked at their whole process. 15% EGFR del in '13 missed. Updated, revalidation, now confirming for 3 mos #PMWC17
4:59pm January 24th 2017 via Twitter Web Client
Tsongalis: Shared samples with other lab that was also validating. Got the unwanted call "sample #7 had an exon 19 del" #PMWC17
4:58pm January 24th 2017 via Twitter Web Client
Tsongalis: For their validation - what caught them was their data analysis. #PMWC17
4:57pm January 24th 2017 via Twitter Web Client
Tsongalis: If you can't afford to validate a test properly, perhaps you shouldn't be running it. #PMWC17
4:56pm January 24th 2017 via Twitter Web Client
Tsongalis: Their method called CGAT - a close look at data analytics. Just b/c you have an instrument and kit, you still need QC #PMWC17
4:55pm January 24th 2017 via Twitter Web Client
Greg Tsongalis (Dartmouth Hitchcock) QC: Where the rubber meets the road #PMWC17
4:53pm January 24th 2017 via Twitter Web Client
Aisner: Showed poor quality FFPE QC, many pages of artifacts, still picked up EGFR exon 19 del #PMWC17
4:52pm January 24th 2017 via Twitter Web Client
Aisner: NGS metrics: % mapped. What happened to non-mapped? Amt of soft clipping? On-board QC (PhiX) #PMWC17
4:49pm January 24th 2017 via Twitter Web Client
Aisner: Flexibility important; what the quality is of the input - fluorometric, microgel, real-time PCR. 'None is foolproof' #PMWC17
4:48pm January 24th 2017 via Twitter Web Client
Aisner: Need to look at matrix effects - components of human tisue. Fixatives, processing. Metrics to establish: extracted nucl acid #PMWC17
4:46pm January 24th 2017 via Twitter Web Client
Aisner: Sharing a subset of slides presented at the FDA - webcast here https://t.co/LcTeIL5Q6c #PMWC17
4:45pm January 24th 2017 via Twitter Web Client
Dana Aisner (Univ CO SOM): Confronting and mitigating pre-analytic variability #PMWC17
4:43pm January 24th 2017 via Twitter Web Client
RT @LincolnNadauld: Three major hurdles of implementing #precisionmedicine: 1) interpreting data, 2) drug procurement, and 3) payment. #PMW…
2:19pm January 24th 2017 via Twitter Web Client
RT @DrKhouryCDC: It’s Time for Nationwide Lynch Syndrome Screening. By @HHampel1 https://t.co/bXdCacz1ZX #PMWC17 https://t.co/zou8fnHGwr
12:49pm January 24th 2017 via Twitter Web Client
RT @GuneetWalia: The tech that'll allow BGI & @CompleteGenomic to sequence 100,000 genomes/yr at <$100- DNA nanoball sequencing- Rade
12:48pm January 24th 2017 via Twitter Web Client
RT @GuneetWalia: Drmanac @CompleteGenomic acquired by BGI, shares promising DNA nanoball-based sequencing for #PrecisionMedicine #PMWC17 #N…
12:47pm January 24th 2017 via Twitter Web Client
RT @BillGates: Life-changing discoveries often get their start as government-funded research at a university: https://t.co/a9op6b6oV7 https…
10:20am December 1st 2016 via Twitter Web Client
Linderman: 3% of lung ca, has exon 14 skip, crizotinib skipping. Sequencing of introns - where the pathology lies... #AMP2016
11:24am November 12th 2016 via Twitter Web Client
Linderman: MET in NSCLC, a complicated story can co-exist w/other oncogene muts. MET-inh not effective. NGS for exon 14 splicing #AMP2016
11:23am November 12th 2016 via Twitter Web Client
Linderman: RET in NSCLC, different partners in lung ca - KIF5B, CDD6, NCOA4. Hard via FISH or IHC. #AMP2016
11:22am November 12th 2016 via Twitter Web Client
Linderman: Many more inh in dev; not enough evidence for routine ERBB2 testing. #AMP2016
11:21am November 12th 2016 via Twitter Web Client
Linderman: For ERBB2 (HER2) in NSCLC, same gene, completely different mechanism. Lung: exon 20, activation, same tests not useful #AMP2016
Linderman: #AMP2016 For BRAF and lung ca - recent paper, PhII data, 33% resp to V600E dabrafenib https://t.co/i2uWcjywgO
11:20am November 12th 2016 via Twitter Web Client
Linderman: Single-gene KRAS still useful as 30% of adenocarcinomas. 'It is what we think is useful for std of care' #AMP2016
11:19am November 12th 2016 via Twitter Web Client
Linderman: KRAS in NSCLC, no effective direct inhibitor; recent reports to target MEK-inh. Useful to 'rule-out' other muts #AMP2016
11:18am November 12th 2016 via Twitter Web Client
Linderman: Other genes: BRAF, ERBB2, KRAS, MET. not mutually exclusive. Limited evid for clinical utility. Can be part of panel #AMP2016
11:17am November 12th 2016 via Twitter Web Client
Linderman: RNA methods 'not established well', nor DNA methods, but expect progress in this area #AMP2016
11:16am November 12th 2016 via Twitter Web Client
Linderman: '14 NEJM https://t.co/S8f57syxUM No designated Companion Dx (CDx), 'you are safe w/FISH'. #AMP2016
11:15am November 12th 2016 via Twitter Web Client
Linderman: ROS1 pos, Rx crizotinib, good response, relapse after 2+ y, new Rx, still in remission. ROS1+ resp to crizotinib #AMP2016
11:13am November 12th 2016 via Twitter Web Client
Linderman: Other genes to test? ROS1, RET, BRAF... Case study ROS1, 73yo M, adeno IIIA, EGFR, KRAS ALK neg. Plat. Rx, liver met #AMP2016
11:12am November 12th 2016 via Twitter Web Client
Linderman: NGS methods unproven for cfDNA, PCR methods appropriate (digital or real-time). No recommendation re:reporting #AMP2016
11:10am November 12th 2016 via Twitter Web Client
Linderman: Sample proc is critical - Sreck or EDTA if processed in hours. Different centrifugation level (no brakes) #AMP2016
Linderman: More work to be done. Acquired resistance - sensitivity is high 60-80%, specificity high. Treat if plasma-pos #AMP2016
11:09am November 12th 2016 via Twitter Web Client
Linderman: For initial Dx - only if tissue unavailable. Monitoring is 'very exciting, very unproven', cannot recommend at present #AMP2016
11:08am November 12th 2016 via Twitter Web Client
Linderman: Clinical utility for ctDNA has 'lots of buzz, evolving'. CTC not ready. 3 contexts: Dx, monitoring, acquired resist. #AMP2016
11:07am November 12th 2016 via Twitter Web Client
Linderman: ASCO poster: https://t.co/MXcOOHbiIN Relapse tests for T790M have to be sensitive; thus lowered to 4% #AMP2016
11:06am November 12th 2016 via Twitter Web Client
Linderman: Shows poster from ASCO '16 - plasma, tissue and urine ID unique and overlapping T790M #AMP2016
11:04am November 12th 2016 via Twitter Web Client
Linderman: Showing cfDNA as an option to biopsy. For EGFR, shows figure from Guardant Health over progression and time of Rx #AMP2016
11:03am November 12th 2016 via Twitter Web Client
Linderman: Illustrates heterogeneity in response to TKI, emergence of clones. Waterfall plot '16 ref https://t.co/SpojdsIWfz #AMP2016
11:02am November 12th 2016 via Twitter Web Client
Linderman: Shows 5w response w/scans, clearing in liver and bone. Heavily pre-treated, still sensitivity was retained #AMP2016
11:00am November 12th 2016 via Twitter Web Client
Linderman: Progressed, put on Doxataxel, did cfDNA test w/T790 mut, Osimertinib, very good response. #AMP2016
